Role of uncoupling protein 1 in the anti-obesity effect of β3-adrenergic agonist in the dog

被引:13
|
作者
Omachi, A. [2 ]
Matsushita, Y. [2 ]
Kimura, K. [2 ]
Saito, M. [1 ]
机构
[1] Tenshi Coll, Sch Nursing & Nutr, Dept Nutr, Sapporo, Hokkaido 0650013, Japan
[2] Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Biochem Lab, Sapporo, Hokkaido 0600818, Japan
关键词
uncoupling protein 1; obesity; dog; beta 3-adrenoceptor agonist; isolated adipocytes; oxygen consumption;
D O I
10.1016/j.rvsc.2007.11.003
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
We have reported that chronic treatment with beta 3-adrenoceptor agonists reduces body fat content and induces the expression of mitochondrial thermogenic uncoupling protein 1 (UCP1) in adipose tissue in the dog. To evaluate the role of UCP1 in the anti-obesity effect of the agonists, we isolated adipocytes from subcutaneous fat pad of beagles before and after a 2-week treatment with AJ-9677, a specific beta 3-adrenoceptor agonist, and examined their thermogenic activity in vitro. Histological and protein analysis revealed that adipose tissues before the treatment were composed of unilocular cells filled with a single large droplet, while the tissues after the treatment contained many smaller and some multilocular adipocytes expressing UCP1 and abundant mitochondrial proteins. Before the treatment, oxygen consumption rate was very low and did not change even when the cells were stimulated by AJ-9677. Two-week AJ-9677 treatment increased basal oxygen consumption rate by 7-fold, and produced a clear responsiveness to AJ-9677 stimulation. Thus, chronic treatment with AJ-9677 induced UCP1 in adipocytes, where oxygen consumption increased in response to AJ-9677 stimulation. It was suggested that UCP1-dependent energy expenditure in adipose tissue contributes to the anti-obesity effect of beta 3-adrenoceptor agonist in dogs. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:214 / 219
页数:6
相关论文
共 50 条
  • [1] Orally bioavailable β3-adrenergic receptor agonist as an anti-obesity agent
    Pardridge, WM
    DRUG DISCOVERY TODAY, 2001, 6 (02) : 104 - 104
  • [2] Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
    Dabrowska, Anna Maria
    Dudka, Jaroslaw
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [3] Role of insulin and Uncoupling protein 1 in glucose lowering effect of β3-adrenergic stimulation
    Zouhar, P.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [4] Effect of postnatal age anti a β3-adrenergic agonist (Zeneca D7114) administration on uncoupling protein-1 abundance in the lamb
    Bird, JA
    Mostyn, A
    Clarke, L
    Juniper, DT
    Budge, H
    Stephenson, T
    Symonds, ME
    EXPERIMENTAL PHYSIOLOGY, 2001, 86 (01) : 65 - 70
  • [5] Anti-obesity and metabolic efficacy of the 3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°C
    Xiao, Cuiying
    Goldgof, Margalit
    Gavrilova, Oksana
    Reitman, Marc L.
    OBESITY, 2015, 23 (07) : 1450 - 1459
  • [6] Associations between polymorphisms in uncoupling protein 2 and in β3-adrenergic receptor and obesity in Koreans
    Hong, Y
    Oh, R
    Sung, Y
    DIABETES, 2001, 50 : A533 - A533
  • [7] Indispensable role of UCP1 for anti-obesity effect of beta-3-adrenergic agonists
    Saito, M
    Inokuma, K
    Omachi, A
    Matsushita, Y
    Kimura, K
    Yamashita, H
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S8 - S8
  • [8] Anti-obesity effects of selective agonists to the β3-adrenergic receptor in dogs.: II.: Recruitment of thermogenic brown adipocytes and reduction of adiposity after chronic treatment with a β3-adrenergic agonist
    Sasaki, N
    Uchida, E
    Niiyama, M
    Yoshida, T
    Saito, M
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 1998, 60 (04): : 465 - 469
  • [9] Uncoupling proteins 2 and 3 with age:: Regulation by fasting and β3-adrenergic agonist treatment
    Scarpace, PJ
    Kumar, MV
    Li, H
    Tümer, N
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2000, 55 (12): : B588 - B592
  • [10] β3-Adrenergic receptor agonists and other potential anti-obesity agents -: art. no. 69
    Vansal, SS
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 2004, 68 (03) : 1 - 10